Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

sutetinib (SZMD4)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jiangsu Suzhong Pharma, Medolution, Teligene

Drug class:

EGFR inhibitor

Related drugs:

‹

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

›

EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	SZMD4 Sensitive: C2 – Inclusion Criteria SZMD4 Sensitive : C2	SZMD4 Sensitive: C2 – Inclusion Criteria SZMD4 Sensitive : C2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	SZMD4 Sensitive: C2 – Inclusion Criteria SZMD4 Sensitive : C2	SZMD4 Sensitive: C2 – Inclusion Criteria SZMD4 Sensitive : C2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	SZMD4 Sensitive: C2 – Inclusion Criteria SZMD4 Sensitive : C2	SZMD4 Sensitive: C2 – Inclusion Criteria SZMD4 Sensitive : C2